MicroRNAs in metabolic disease.
MicroRNAs in metabolic disease.
复制标题
DOI：
10.1161/atvbaha.112.300144
复制
发表时间：
2013-02
期刊：
影响因子：
--
通讯作者：
Suárez Y
中科院分区：
文献类型：
--
作者：
Fernández-Hernando C;Ramírez CM;Goedeke L;Suárez Y
脂质和葡萄糖稳态的代谢控制的改变使个体易于发展心脏代谢疾病，如2型糖尿病和动脉粥样硬化。过去几年的研究表明，miRNAs在调节这些生理过程中起着重要作用。miR-33是一种在Srebp基因中编码的内含子miRNA，它是miRNA在调节代谢中的贡献的一个例子。miR-33控制细胞胆固醇输出和脂肪酸降解，而其宿主基因刺激胆固醇和脂肪酸合成。其他miRNA，如miR-122，也通过控制肝脏中的胆固醇合成和脂蛋白分泌在调节脂质稳态中发挥关键作用。本文综述了该领域的最新研究成果，重点介绍了miRNAs在调节糖脂代谢中的作用。我们还将讨论如何特定的miRNAs的调制可能是一个有前途的策略来治疗代谢性疾病。
Alterations in the metabolic control of lipid and glucose homeostasis predispose an individual to develop cardiometabolic diseases such as type 2-diabetes and atherosclerosis. Work over the last years has suggested that miRNAs play an important role in regulating these physiological processes. The contribution of miRNAs in regulating metabolism is exemplified by miR-33, an intronic miRNA encoded in the Srebp genes. miR-33 controls cellular cholesterol export and fatty acid degradation while its host genes stimulate cholesterol and fatty acid synthesis. Other miRNAs, such as miR-122, also play a critical role in regulating lipid homeostasis by controlling cholesterol synthesis and lipoprotein secretion in the liver. This review article summarizes the recent findings in the field, highlighting the contribution of miRNAs in regulating lipid and glucose metabolism. We will also discuss how the modulation of specific miRNAs may be a promising strategy to treat metabolic diseases.